Bausch Health Companies | VRX - Interest Expense On Debt



Bausch Health Companies reported $465M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
Amgen USD 694M 29M Jun/2025
ANI Pharmaceuticals USD 5.44M 46K Jun/2025
Aurora Cannabis CAD 1.78M 491K Jun/2025
Bausch Health Companies USD 465M 135M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Canopy Growth CAD 9.74M 7.03M Jun/2025
Corcept Therapeutics 6M 6M Jun/2024
Danaher USD 71M 1000K Jun/2025
Drreddys Laboratories INR 817M 60M Dec/2024
Eli Lilly USD 249M 5.3M Jun/2025
Gilead Sciences USD 254M 6M Jun/2025
Novo Nordisk 4.96B 225M Jun/2025
Pacira USD 3.82M 110K Jun/2025
Perrigo 39.6M 600K Jun/2025
Prestige Brands USD 10.2M 275K Jun/2025
Supernus Pharmaceuticals USD 0 0 Dec/2024
Vertex Pharmaceuticals USD 3.7M 900K Jun/2025
Zoetis USD 53M 1000K Jun/2025